Hereditary motor neuropathies.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
17
8
2020
medline:
8
5
2021
entrez:
16
8
2020
Statut:
ppublish
Résumé
Hereditary motor neuropathies (HMN) comprise a broad genotypic and phenotypic spectrum of rare, progressively disabling diseases manifesting with length-dependent muscle weakness and atrophy. To date, more than half of the cases cannot be genetically explained. To provide symptomatic and disease-modifying treatments in the future, a better understanding of disease mechanisms is required. By whole exome and genome sequencing, the discovery of several novel genes (SCO2, TDRKH, SPTAN1, CADM3, and SORD) involved in the pathogenesis of HMN has now relevantly changed the pathophysiological knowledge. This recent success in causative understanding has mainly been driven by the development of functional models including cell culture, animal, and patient-derived induced pluripotent stem cell platforms. These models have an important impact on therapeutic advances including broader approaches to prevent or reverse axonal degeneration and individualized gene silencing attempts using sequence-specific RNA degradation mechanisms. In rare diseases such as HMN, the recent development of genetic sequencing and data interpretation methods has enabled a broader diagnostic approach, whereas treatment strategies are becoming more individualized. Significant milestones have been reached in the discovery of new genes, the establishment of functional disease models, and the preclinical development of mechanistic-based therapies.
Identifiants
pubmed: 32796276
doi: 10.1097/WCO.0000000000000848
pii: 00019052-202010000-00006
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
568-574Références
Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motor neuropathies. J Neurol Neurosurg Psychiatry 2012; 83:614.
Cortese A, Wilcox JE, Polke JM, et al. Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease. Neurology 2020; 94:e51e61.
Bansagi B, Griffin H, Whittaker RG, et al. Genetic heterogeneity of motor neuropathies. Neurology 2017; 88:12261234.
Weis J, Claeys KG, Roos A, et al. Towards a functional pathology of hereditary neuropathies. Acta Neuropathol 2017; 133:493515.
Magy L, Mathis S, Le Masson G, et al. Updating the classification of inherited neuropathies: results of an international survey. Neurology 2018; 90:e870e876.
Saporta MA, Dang V, Volfson D, et al. Axonal Charcot–Marie–Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp Neurol 2015; 263:190199.
Kim J-Y, Woo S-Y, Hong YB, et al. HDAC6 inhibitors rescued the defective axonal mitochondrial movement in motor neurons derived from the induced pluripotent stem cells of peripheral neuropathy patients with HSPB1 mutation. Stem Cells Int 2016; 2016:9475981.
Kang K-h, Han JE, Hong YB, et al. Human HSPB1 mutation recapitulates features of distal hereditary motor neuropathy (dHMN) in Drosophila. Biochem Biophys Res Commun 2020; 521:220226.
Haidar M, Asselbergh B, Adriaenssens E, et al. Neuropathy-causing mutations in HSPB1 impair autophagy by disturbing the formation of SQSTM1/p62 bodies. Autophagy 2019; 15:10511068.
Shy M, Rebelo AP, Feely SM, et al. Mutations in BAG3 cause adult-onset Charcot-Marie-Tooth disease. J Neurol Neurosurg Psychiatry 2018; 89:313315.
Al-Tahan S, Weiss L, Yu H, et al. New family with HSPB8-associated autosomal dominant rimmed vacuolar myopathy. Neurol Genet 2019; 5:e349.
Lassuthova P, Rebelo AP, Ravenscroft G, et al. Mutations in ATP1A1 cause dominant Charcot-Marie-Tooth type 2. Am J Hum Genet 2018; 102:505514.
Manganelli F, Parisi S, Nolano M, et al. Insights into the pathogenesis of ATP1A1-related CMT disease using patient-specific iPSCs. J Peripher Nerv Syst 2019; 24:330339.
Kennerson ML, Nicholson GA, Kaler SG, et al. Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy. Am J Hum Genet 2010; 86:343352.
Perez-Siles G, Grant A, Ellis M, et al. Characterizing the molecular phenotype of an Atp7a T985I conditional knock in mouse model for X-linked distal hereditary motor neuropathy (dHMNX). Metallomics 2016; 8:981992.
Perez-Siles G, Cutrupi A, Ellis M, et al. Modelling the pathogenesis of X-linked distal hereditary motor neuropathy using patient-derived iPSCs. Dis Model Mech 2020; 13:dmm041541.
Rebelo AP, Saade D, Pereira CV, et al. SCO2 mutations cause early-onset axonal Charcot-Marie-Tooth disease associated with cellular copper deficiency. Brain 2018; 141:662672.
Beijer D, Deconinck T, De Bleecker JL, et al. Nonsense mutations in alpha-II spectrin in three families with juvenile onset hereditary motor neuropathy. Brain 2019; 142:26052616.
Previtali SC, Zhao E, Lazarevic D, et al. Expanding the spectrum of genes responsible for hereditary motor neuropathies. J Neurol Neurosurg Psychiatry 2019; 90:11711179.
Miura S, Kosaka K, Nomura T, et al. TDRKH is a candidate gene for an autosomal dominant distal hereditary motor neuropathy. Eur J Med Genet 2019; 62:103594.
Lee DC, Meyer-Schuman R, Bacon C, et al. A recurrent GARS mutation causes distal hereditary motor neuropathy. J Peripher Nerv Syst 2019; 24:320323.
Morelli KH, Griffin LB, Pyne NK, et al. Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models. J Clin Invest 2019; 129:55685583.
Li J-Q, Dong H-L, Chen C-X, Wu Z-Y. A novel WARS mutation causes distal hereditary motor neuropathy in a Chinese family. Brain 2019; 142:e49e149.
Wang B, Li X, Huang S, et al. A novel WARS mutation (p. Asp314Gly) identified in a Chinese distal hereditary motor neuropathy family. Clin Genet 2019; 96:176182.
Feng SY, Li LY, Feng SM, Zou ZY. A novel VRK1 mutation associated with recessive distal hereditary motor neuropathy. Ann Clin Transl Neurol 2019; 6:401405.
Greenbaum L, Barel O, Nikitin V, et al. Identification of a homozygous VRK1 mutation in two patients with adult-onset distal hereditary motor neuropathy. Muscle Nerve 2020; 61:395400.
Li N, Wang L, Sun X, et al. A novel mutation in VRK1 associated with distal spinal muscular atrophy. J Hum Genet 2019; 64:215219.
Akçimen F, Vural A, Durmuş H, et al. A novel homozygous FBXO38 variant causes an early-onset distal hereditary motor neuronopathy type IID. J Hum Genet 2019; 64:11411144.
Rebelo AP, Cortese A, Abraham A, et al. A CADM3 variant causes CMT2 with marked upper limb involvement. (Under review) 2020.
Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet 2020; 52:473481.
Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379:1121.
Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379:2231.
Zhao HT, Damle S, Ikeda-Lee K, et al. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest 2018; 128:359368.
Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377:17231732.
d’Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease. Nat Med 2011; 17:968.
Benoy V, Van Helleputte L, Prior R, et al. HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. Brain 2018; 141:673687.
Benoy V, Berghe PV, Jarpe M, et al. Development of improved HDAC6 inhibitors as pharmacological therapy for axonal Charcot–Marie–Tooth disease. Neurotherapeutics 2017; 14:417428.
Rossaert E, Van Den Bosch L. HDAC6 inhibitors: translating genetic and molecular insights into a therapy for axonal CMT. Brain Res 2020; 1733:146692.
Geisler S, Huang SX, Strickland A, et al. Gene therapy targeting SARM1 blocks pathological axon degeneration in mice. J Exp Med 2019; 216:294303.
Samsam M, Mi W, Wessig C, et al. The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J Neurosci 2003; 23:28332839.
Meyer zHG, Miesbach T, Muller J, et al. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays posttraumatic axonal degeneration. Neurobiol Dis 2011; 42:1.
Kwak JY, Kwon K-S. Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia. Ann Geriatr Med Res 2019; 23:98104.
Glasser CE, Gartner MR, Wilson D, et al. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve 2018; 57:921926.